Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

It's time for chronotherapy!

B Coudert1, C Focan, E Donato di Paola

  • 1Centre Georges François Leclerc, 1 rue du Professeur Marion, BP 77980, 21079, Dijon cedex, France. bcoudert@dijon.fnclcc.fr

European Journal of Cancer (Oxford, England : 1990)
|February 23, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Auto-Immune Pancreatitis with Pseudo-Tumoral Mass Induced by Pembrolizumab in a Woman suffering from Metastatic Urothelial Carcinoma: Case Report and Literature survey.

Acta gastro-enterologica Belgica·2026
Same author

Stauffer syndrome : a rare paraneoplastic complication of renal cell carcinoma to be kept in mind. Case report and literature survey.

Acta gastro-enterologica Belgica·2024
Same author

Patient management after primary rectal cancer diagnosis. Special focus on surgical treatment for non-metastatic disease.

Acta chirurgica Belgica·2023
Same author

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer.

ESMO open·2021
Same author

Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME).

ESMO open·2021
Same author

Population pharmacokinetics and exposure-response relationship of trastuzumab and bevacizumab in early-stage breast cancer.

European journal of clinical pharmacology·2021
Same journal

Early-onset colorectal cancer across Europe: Burden, mechanisms, and health-system implications.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinical urgency of incidental findings in the first year of the 4-IN-THE-LUNG-RUN lung cancer screening program.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Left behind but not left alone: Excluded cell populations in the non-small cell lung cancer stroma predict superior long-term overall survival.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS).

European journal of cancer (Oxford, England : 1990)·2026
See all related articles

The EORTC Chronotherapy Group (CTG) investigates timed cancer treatments based on biological rhythms. This research aims to improve cancer therapy delivery and patient outcomes by adapting treatments to circadian rhythms.

Area of Science:

  • Oncology
  • Chronobiology
  • Clinical Cancer Research

Background:

  • The International Organisation for Cancer Chronotherapy (IOCC) pioneered large-scale chronotherapy trials.
  • Programmable pumps and actigraph devices were developed for cancer chronotherapy.
  • The EORTC Chronotherapy Group (CTG) evolved from the IOCC, leveraging expertise in cancer research.

Purpose of the Study:

  • To investigate the relevance of chronomodulated (timed) cancer therapy administration.
  • To explore the impact of biological rhythms on cancer treatment efficacy.
  • To advance the field of cancer chronotherapy through multicentre trials and collaborations.

Main Methods:

  • Conducting multicentre international chronotherapy trials.
  • Utilizing programmable pumps for chronodelivery of cytotoxic agents.

Related Experiment Videos

  • Employing actigraph devices to monitor circadian rhythm alterations in cancer patients.

    • Main Results:

    • The EORTC CTG has expanded significantly, now including 48 centers in 12 countries.
    • Seven multicentre chronotherapy trials are currently underway.
    • The group focuses on adapting cancer treatment delivery to circadian rhythms.

    Conclusions:

    • The EORTC CTG is establishing a comprehensive chronotherapy network.
    • Collaborations span experimental chronobiology, drug testing, and patient management.
    • The ultimate goal is to improve quality of life and survival in cancer patients through chronotherapy.